NCI invites R01 applications to develop and apply in vivo molecular imaging to unravel how inflammation shapes cancer initiation, progression, and treatment response. Projects must be multidisciplinary—co-led by imaging and cancer biology investigators—and advance quantitative, multimodal imaging probes/approaches that illuminate immune–tumor interactions and improve monitoring of therapy.
Eligibility Criteria:
-
U.S.-based higher education institutions; nonprofits (with/without 501(c)(3)); for-profit organizations (including small businesses).
-
State, county, city/township, special district governments; independent school districts; public housing authorities.
-
Federally recognized tribal governments and other eligible tribal organizations; faith-based/community-based and regional organizations; eligible federal agencies.
-
Foreign organizations are not eligible; foreign components of U.S. organizations are allowed.
-
Multiple PD/PI required: at least one in imaging and one in cancer basic science (e.g., biology, immunology, inflammation).
Funding Details:
-
Activity code: R01; clinical trial not allowed
-
Direct costs: less than 500,000 USD per year (must match project needs)
-
Project period: up to 5 years
Deadline:
-
Standard NIH due dates through 2025–2027 (e.g., February 5, June 5, October 5 for new applications); expires January 8, 2028.
-
Applications due 5:00 PM local time of applicant organization.
Where to Go for Further Information:
-
Scientific contact: Charles Lin, Ph.D. — [email protected].
-
General grants info: [email protected].
-
Submission support: Grants.gov Support — [email protected].